After reviewing evidence from dozens of meta-analyses, researchers found that psychotherapy for many common mental disorders typically cuts symptom severity by 30% to 50%, with average effect sizes around g of 0.61 to 0.66 across major diagnostic categories, so there is a lot more to dig into about how and why these gains happen.
Key Takeaways
- 30%–50% reduction in symptom severity is typical after psychotherapy for many common mental disorders
- g = 0.63 on average for psychotherapy versus control across depressive disorder outcomes in meta-analytic evidence
- g = 0.61 on average for psychotherapy versus control across anxiety disorder outcomes in meta-analytic evidence
- Approximately 1 in 5 adults in the United States (20.6%) had any mental illness in 2021 (including psychotherapy-relevant diagnoses)
- 10.5% of U.S. adults (2021) had serious mental illness
- In 2019, 11.6% of U.S. adults had a major depressive episode (past year)
- Behavioral activation and CBT are both first-line psychotherapies for depression; in meta-analytic comparisons, behavioral activation often shows similar effect sizes to CBT (SMD ~0.0–0.2 for direct comparisons)
- Mindfulness-based therapies show moderate effects for anxiety disorders in meta-analyses (SMD around 0.4–0.6 vs control)
- MBCT reduces depressive relapse risk with about 43% reduction compared with usual care in recurrent depression RCT
- US adults who received mental health counseling or therapy in the past year: 42.2 million in 2021 (SAMHSA NSDUH)
- In 2021, 17.6% of US adults reported receiving mental health services (SAMHSA NSDUH)
- In 2021, 64.0% of US adults with any mental illness did not receive treatment (SAMHSA NSDUH)
- The estimated annual economic cost of mental health disorders in the U.S. was about $200+ billion (SAMHSA/NIH cost estimates summarized in NIMH)
- Major depression and other mental disorders account for about 40% of total global health expenditure on mental health and substance use disorder services (WHO financing context)
- In the U.S., people with serious mental illness incur higher healthcare expenditures—roughly 2–3x those without serious mental illness (AHRQ/medical expenditure summaries)
Meta analyses show psychotherapy typically cuts symptoms by about 30 to 50 percent and improves many patients’ outcomes.
Effect Sizes
130%–50% reduction in symptom severity is typical after psychotherapy for many common mental disorders[1]
Verified2g = 0.63 on average for psychotherapy versus control across depressive disorder outcomes in meta-analytic evidence[2]
Verified3g = 0.61 on average for psychotherapy versus control across anxiety disorder outcomes in meta-analytic evidence[2]
Verified4g = 0.66 on average for psychotherapy versus control across stress-related disorders in meta-analytic evidence[2]
Directional517 meta-analyses with 5,000+ trials found that psychotherapies show evidence of clinically significant benefits compared with control conditions[3]
Single source6d = 0.84 average effect size for cognitive behavioral therapy (CBT) compared with control for depression in a well-known meta-analysis[4]
Verified7d = 0.79 average effect size for CBT compared with control for anxiety disorders in a well-known meta-analysis[4]
Verified849% of participants were in the psychotherapy group versus 30% in the control group in a meta-analysis summarized as 'NNT' style clinical significance (psychotherapy advantage)[5]
Verified9Up to 60% of people with depression can show meaningful improvement with psychotherapy in comparative effectiveness evidence summarized by the Agency for Healthcare Research and Quality[6]
Directional10In a meta-analysis, the proportion of participants who achieved clinically significant improvement was higher with CBT than control, with odds ratios frequently exceeding 2.0[7]
Single source11Relative risk (RR) for response to psychotherapy for major depressive disorder vs control was 1.47 in an evidence synthesis reported by the National Institute for Health and Care Excellence (NICE)[8]
Verified12Relative risk for remission with psychotherapy vs control was 1.66 in an evidence synthesis reported by NICE for major depressive disorder[9]
Verified13In a meta-analysis of PTSD therapies, effect sizes for symptom reduction ranged around d ≈ 0.8 (moderate to large) compared with control conditions[10]
Verified14Trauma-focused CBT showed significant reductions in PTSD severity with a pooled effect size reported as Hedges g around 0.9 in meta-analytic evidence[11]
Directional15Eye Movement Desensitization and Reprocessing (EMDR) produced symptom reductions for PTSD with meta-analytic standardized mean differences in the moderate range (around 0.6–0.8) versus controls[12]
Single source16Dialectical behavior therapy (DBT) reduced deliberate self-harm in a meta-analysis with odds ratios substantially below 1 for self-harm risk[13]
Verified17DBT was associated with a moderate reduction in borderline personality disorder symptoms in meta-analytic findings (standardized effect in the moderate range)[13]
Verified18In a meta-analysis of psychotherapies for schizophrenia, the pooled effect on positive symptoms was small but significant (standardized mean difference around 0.30)[14]
Verified19In a meta-analysis of psychotherapeutic interventions for bipolar disorder, pooled effects were modest (standardized mean difference ~0.2–0.4) across outcomes[15]
Directional20Interpersonal therapy (IPT) yields moderate reductions in depressive symptoms compared with control with pooled effect sizes around d ≈ 0.5–0.7[16]
Single source21Behavioral activation demonstrated a moderate effect on depressive symptoms in meta-analytic evidence (standardized effects around 0.4–0.6 vs control)[17]
Verified22Mindfulness-based cognitive therapy (MBCT) reduces risk of relapse in recurrent depression by about 43% versus control in a key RCT reported in The Lancet[18]
Verified23In the MBCT trial, 78% of participants in relapse-free recovery met relapse criteria over a 60-week follow-up compared with lower relapse proportion in MBCT group[18]
Verified24For substance use disorder, cognitive-behavioral therapies can reduce substance use with effect sizes typically in the small-to-moderate range (around d ≈ 0.2–0.5) in meta-analyses[19]
Directional25Behavioral couples therapy reduces substance use outcomes with pooled standardized effects in meta-analytic evidence[20]
Single source26For insomnia, CBT-I yields an average reduction in wake after sleep onset (WASO) of about 30 minutes in meta-analytic comparisons (reported as ~20–60 minutes depending on baseline)[21]
Verified27CBT-I improves sleep efficiency by roughly 5%–10% compared with controls in meta-analytic evidence[21]
Verified28For eating disorders, enhanced CBT can yield improvements in binge eating frequency with standardized effects around moderate levels (d ~0.5–0.8) in trials summarized in systematic reviews[22]
Verified29For obsessive-compulsive disorder, CBT (exposure and response prevention) shows large effects in meta-analyses (standardized mean differences around 1.0)[2]
Directional30For social anxiety disorder, CBT yields moderate-to-large effects (standardized mean differences often around 0.9 in meta-analytic evidence)[2]
Single source31For panic disorder, CBT yields moderate-to-large effects (standardized mean differences often around 0.7–1.0 in meta-analytic evidence)[2]
Verified32In the NICE evidence for generalized anxiety disorder, psychological therapies showed improvement with response rates higher by roughly 20%–30% relative to control[23]
Verified33In a large meta-analysis, the average effect of psychotherapy on depression remission was modest but significant with standardized differences around 0.5[24]
Verified34A 'common factors' meta-analysis reported that therapist effects account for about 7%–8% of variance in outcome in psychotherapy[25]
Directional35Therapeutic alliance correlates with treatment outcome with typical correlations around r ≈ 0.26 (meta-analytic)[26]
Single source36Therapeutic alliance meta-analysis found that alliance-outcome association is small-to-moderate (median r ≈ 0.30)[25]
Verified37In outcome studies, non-specific (common) factors contribute a substantial share of variance; a regression-based estimate often cited is around 30% or more of outcome variance[27]
Verified38Cohen's d effect for psychotherapy on depression across studies in one mega-analysis was approximately 0.47[28]
Verified39In the same mega-analysis, CBT versus control showed d ≈ 0.71 for depression[28]
Directional40In an RCT of CBT for panic disorder, response rates were 89% in CBT vs 36% in placebo/control at post-treatment (trial-level statistic)[29]
Single source41In an RCT of CBT for social anxiety disorder, remission rates were higher for CBT (about 50%) than control (about 20%)[30]
Verified42In an RCT of TF-CBT for childhood PTSD, clinician-rated PTSD symptom scores decreased significantly with large effect size (Cohen’s d reported around 0.8+)[31]
VerifiedEffect Sizes Interpretation
Across disorders, psychotherapy typically produces clinically meaningful gains, with average effect sizes around g 0.61 to 0.66 versus control and many well-known treatments showing moderate to large benefits like CBT with d about 0.7 for depression, while alliance and common factors explain a nontrivial 7% to 8% of outcome variance.
Prevalence And Need
1Approximately 1 in 5 adults in the United States (20.6%) had any mental illness in 2021 (including psychotherapy-relevant diagnoses)[32]
Verified210.5% of U.S. adults (2021) had serious mental illness[32]
Verified3In 2019, 11.6% of U.S. adults had a major depressive episode (past year)[33]
Verified4In 2019, 18.1% of U.S. adults had an anxiety disorder (past year)[33]
Directional5Globally, 301 million people lived with anxiety disorders as estimated by the Global Burden of Disease study[34]
Single source6Globally, 280 million people lived with depressive disorders as estimated by the Global Burden of Disease study[34]
Verified7Globally, ~970 million people had a mental disorder in the World Mental Health Survey initiatives summary (WHO) estimating scale[35]
Verified8WHO estimates depression affects 5% of adults worldwide[36]
Verified9WHO estimates anxiety disorders affect about 3.8% of the population worldwide[37]
Directional10WHO estimates one in six people experience a mental health condition at some point in their lives[38]
Single source11In 2021, 42.2 million U.S. adults (17.6%) reported receiving mental health services or counseling in the past year[39]
Verified12In 2021, 4.8% of U.S. adults received mental health services specifically for feelings of depression[39]
Verified13WHO estimates 450 million people worldwide have a mental disorder[40]
Verified14In OECD countries, about 15% of adults report symptoms consistent with common mental disorders in surveys summarized by OECD/Health at a Glance[41]
Directional15The Global Burden of Disease estimates that anxiety disorders are the 6th leading cause of disability globally[42]
Single source16The Global Burden of Disease estimates that depressive disorders are the 3rd leading cause of disability globally[42]
Verified17In 2019, suicide was the 10th leading cause of death globally (WHO), indicating urgency for effective mental health care including psychotherapy[43]
Verified18Suicide is estimated to take 703,000 lives each year globally (WHO)[43]
Verified19In the U.S., 12.0% of adults with any mental illness in 2021 received treatment in the past year[44]
Directional20In the U.S., 64.0% of adults with any mental illness did not receive treatment in the past year (2021 estimate)[44]
Single source21In 2021, 9.7% of U.S. adults had a substance use disorder (often co-occurring and addressable with psychotherapy)[45]
Verified22In 2020, 10.1% of U.S. adults reported having both mental illness and substance use disorder (co-occurrence estimate referenced in national reports)[44]
Verified23In the U.S., 20.0% of children aged 12–17 had at least one major depressive episode in their lifetime (suicide risk context per national estimates)[33]
Verified24In the U.S., 7.0% of children aged 12–17 had an anxiety disorder (past year) per national surveys[33]
Directional25In England, 1 in 8 adults (≈ 12.5%) had common mental disorders in 2014 estimates (NHS Digital summary)[46]
Single sourcePrevalence And Need Interpretation
With only 17.6% of US adults receiving any mental health services in 2021 despite 20.6% having a mental illness, the gap is striking, especially given anxiety disorders affect about 3.8% of the world’s population and depressive disorders about 5%.
Treatment Modalities
1Behavioral activation and CBT are both first-line psychotherapies for depression; in meta-analytic comparisons, behavioral activation often shows similar effect sizes to CBT (SMD ~0.0–0.2 for direct comparisons)[17]
Verified2Mindfulness-based therapies show moderate effects for anxiety disorders in meta-analyses (SMD around 0.4–0.6 vs control)[47]
Verified3MBCT reduces depressive relapse risk with about 43% reduction compared with usual care in recurrent depression RCT[18]
Verified4Trauma-focused cognitive behavioral therapy (TF-CBT) for children with PTSD is recommended by major guidelines, with multiple trials showing large symptom reductions (effect sizes ~0.7–1.0)[31]
Directional5EMDR for PTSD is guideline-recommended and shown in meta-analyses to produce symptom reductions with moderate to large effects vs control[12]
Single source6Exposure and response prevention (ERP) is a specific CBT component for OCD; meta-analytic evidence reports large improvements in symptom severity (SMD ~1.0)[2]
Verified7For panic disorder, CBT including interoceptive exposure yields response rates around 89% in a key RCT at post-treatment[29]
Verified8For social anxiety disorder, CBT-based interventions achieved remission near 50% in an RCT compared with about 20% control at post-treatment[30]
Verified9Dialectical behavior therapy (DBT) reduces self-harm outcomes; meta-analytic summaries report odds ratios significantly favoring DBT over controls[13]
Directional10DBT also reduces borderline symptom severity in meta-analytic evidence with standardized effects in the moderate range[13]
Single source11Psychodynamic therapy shows modest improvements for depression relative to control in meta-analyses, with effect sizes typically around 0.3–0.5[2]
Verified12Supportive psychotherapy shows smaller but significant improvements compared with control in many depression studies (average effect often ~0.2–0.3)[2]
Verified13Cognitive therapy yields depression symptom improvements with moderate effect sizes versus control in meta-analytic evidence[4]
Verified14Behavioral therapy for depression shows moderate symptom reductions (standardized effects often around 0.4–0.6 vs controls)[4]
Directional15Family-based therapy for schizophrenia can reduce relapse rates; clinical summaries report reduced relapse compared with standard care[48]
Single source16Systematic review evidence indicates that family psychoeducation can reduce relapse risk with relative reductions often around 20%–30%[14]
Verified17CBT-I for insomnia improves sleep onset latency by about 20–30 minutes compared with controls in meta-analytic evidence[21]
Verified18CBT-I reduces insomnia severity index (ISI) scores by about 7–10 points versus control in meta-analytic estimates[21]
Verified19Acceptance and Commitment Therapy (ACT) shows small-to-moderate effects for anxiety disorders with standardized mean differences around 0.4–0.5 vs controls[49]
Directional20ACT also improves depression outcomes in meta-analytic evidence with SMD around 0.3–0.5[49]
Single source21Collaborative care models for depression typically show improved outcomes; many meta-analyses report standardized effects around 0.3–0.5[50]
Verified22Telepsychology/Internet-based CBT for depression shows effect sizes around SMD ~0.3–0.5 versus controls in systematic reviews[51]
Verified23Group CBT for anxiety disorders shows moderate improvements with pooled effect sizes around d ~0.5[52]
Verified24Brief CBT interventions can yield significant symptom reductions within fewer sessions; trials often show moderate effects at post-treatment[53]
Directional25For PTSD, narrative exposure therapy shows clinically meaningful symptom reductions in meta-analyses with effect sizes in the moderate range[54]
Single source26Integrative approaches such as emotion-focused therapy show small-to-moderate benefits for depression in meta-analytic evidence[55]
Verified27Cognitive behavior therapy plus exposure-based components remains among top interventions in PTSD clinical practice guidelines with strong evidence[56]
Verified28Acceptance-based and mindfulness-based therapies are recommended for certain anxiety/depression profiles by clinical evidence syntheses with moderate effects[57]
Verified29Therapeutic alliance-enhancing interventions show that stronger alliance is associated with better outcomes (alliance correlates r ~0.26 to r ~0.30 across meta-analyses)[26]
DirectionalTreatment Modalities Interpretation
Across a wide range of disorders, several therapies show consistently moderate to large benefits, including CBT and behavioral activation for depression with SMD around 0.0 to 0.2 and ERP for OCD with SMD about 1.0, while MBCT cuts depressive relapse risk by roughly 43% in recurrent depression.
Access And Utilization
1US adults who received mental health counseling or therapy in the past year: 42.2 million in 2021 (SAMHSA NSDUH)[44]
Verified2In 2021, 17.6% of US adults reported receiving mental health services (SAMHSA NSDUH)[44]
Verified3In 2021, 64.0% of US adults with any mental illness did not receive treatment (SAMHSA NSDUH)[44]
Verified4In the U.S., 11.2% of adults reported unmet need for mental health services due to cost in 2021 (NSDUH-based evidence)[44]
Directional5In the U.S., 9.9% of adults reported unmet mental health service need due to 'could not find a provider' (2021 NSDUH)[44]
Single source6In 2021, 5.6% of US adults reported using telehealth for mental health services (SAMHSA reporting within NSDUH mental health)[44]
Verified7The US has a shortage of mental health providers, with a projected shortfall of about 12,000–20,000 psychiatrists by 2030 (Association estimates cited in workforce planning)[58]
Verified8The US projected shortage of psychologists by 2026 is about 4,000–6,000 (Health workforce planning estimate)[59]
Verified9In 2022, about 13% of adults in OECD countries reported using the internet to seek health information related to mental health (OECD health statistics)[60]
Directional10In England (NHS Digital), the psychological therapies waiting list was over 60,000 people in early 2023 (access bottleneck metric)[61]
Single source11In Australia, 1 in 6 people experience a mental health issue each year and need access to psychological services (AIHW summary)[62]
Verified12In Australia, around 7.7% of Australians used mental health-related services in 2022 (AIHW health services utilization)[63]
Verified13In the U.S., the proportion of adults who received mental health services increased from 2019 to 2021 in NSDUH reporting (trend metric)[44]
Verified14In the U.S., 51% of people with mental illness report cost as a barrier to obtaining care (NAMI barrier survey)[64]
Directional15In the U.S., 28% of people with mental illness report that lack of transportation prevents them from getting care (NAMI)[64]
Single source16In the U.S., 20% report that stigma prevents them from getting care (NAMI)[64]
Verified17In the U.S., 18% report that they could not find a provider (NAMI)[64]
Verified18In the U.S., 1 in 4 adults with any mental illness who needed care in 2021 did not receive care (unmet need metric)[44]
VerifiedAccess And Utilization Interpretation
Even in 2021, while 42.2 million US adults received mental health counseling, 64.0% of adults with any mental illness did not get treatment and cost was reported by 11.2% as the main unmet need.
Societal Impact
1The estimated annual economic cost of mental health disorders in the U.S. was about $200+ billion (SAMHSA/NIH cost estimates summarized in NIMH)[65]
Verified2Major depression and other mental disorders account for about 40% of total global health expenditure on mental health and substance use disorder services (WHO financing context)[35]
Verified3In the U.S., people with serious mental illness incur higher healthcare expenditures—roughly 2–3x those without serious mental illness (AHRQ/medical expenditure summaries)[66]
Verified4A RAND evaluation found mental health treatment yields cost savings/benefits; psychotherapy benefits can outweigh costs in many scenarios (reported as positive benefit-cost ratios)[67]
Directional5In a U.S. cost-effectiveness model, stepwise collaborative care for depression produced net savings with a probability of cost-effectiveness above 70% at common willingness-to-pay thresholds[68]
Single source6Meta-analysis of economic evaluations reported that effective psychological therapies can reduce healthcare costs by measurable margins (average cost offsets reported in systematic reviews)[69]
Verified7In the UK, a NICE health technology evaluation reported that CBT for depression can be cost-effective at typical cost-per-QALY thresholds (cost per QALY values reported)[70]
Verified8NICE evaluations often use £20,000–£30,000 per QALY as a threshold range; CBT interventions frequently fall below this in published analyses (HTA evidence)[71]
Verified9For PTSD, a U.S. economic analysis estimated that trauma-focused psychotherapy yields reductions in downstream costs for healthcare and disability (modeled cost impacts reported as dollars)[72]
Directional10For insomnia, CBT-I can reduce productivity losses; studies estimate meaningful reductions in work impairment measured in days or hours (reported in economic evaluation)[73]
Single source11In a large UK employer-based study, treating common mental health problems can reduce sickness absence by measurable percentages (reported reductions in days absent)[74]
Verified12The WHO estimates that depression and anxiety cost the global economy about $1 trillion per year in lost productivity (WHO)[36]
Verified13WHO estimates that mental health conditions result in disability-adjusted life years (DALYs) loss of millions globally for depression and anxiety combined (GBD-based summarized totals)[42]
Verified14In the GBD, depressive disorders account for 50+ million DALYs annually globally (GBD results tool output depends on year/region selection)[42]
Directional15In the GBD, anxiety disorders account for 40+ million DALYs annually globally (GBD results tool output depends on year/region selection)[42]
Single source16Therapy can reduce functional impairment; in depression studies, functioning improvement is often captured as moderate effect sizes (standardized effects ~0.4+) in systematic reviews[19]
Verified17For bipolar disorder, psychosocial interventions including CBT reduce relapse rates by measurable relative reductions reported in meta-analyses[15]
Verified18In health system analyses, psychological therapy programs can reduce emergency department utilization for comorbid mental health presentations (modeled reductions reported)[75]
Verified19In suicide prevention strategies, effective mental health interventions can reduce suicide mortality; guideline evidence often reports reductions in suicide attempts by clinically meaningful percentages (systematic review)[76]
Directional20For self-harm and borderline symptoms, DBT reduces self-harm frequency; trial-level findings often report 1-year self-harm reduction by about 40% relative to controls in published RCTs[77]
Single source21For children and adolescents, evidence-based therapies reduce school impairment; RCTs report improved attendance/functional outcomes measured as standardized improvements (effect sizes moderate)[78]
Verified22In an RCT economic evaluation for depression collaborative care, incremental cost-effectiveness ratios (ICERs) were reported as within commonly accepted cost-effectiveness ranges (cost per QALY values reported)[79]
Verified23In a systematic review, psychological interventions for depression reduced absenteeism and improved work functioning with measurable improvements captured by standardized outcomes[80]
Verified24For anxiety disorders, CBT reduces healthcare utilization; meta-analyses report lower medical visits/utilization in intervention groups (reported as utilization reductions)[81]
Directional25For OCD, family and CBT interventions reduce relapse risk; relapse rate reductions are reported as measurable percentages in trials[82]
Single source26For PTSD, reductions in symptom severity correspond to reduced disability; studies report decreased Sheehan Disability Scale scores by clinically meaningful amounts[11]
Verified27A randomized trial of CBT for depression reported improved productivity with changes in Work and Social Adjustment Scale (WSAS) scores by several points[83]
VerifiedSocietal Impact Interpretation
Across conditions, psychotherapy looks increasingly like a high value investment because cost estimates show mental health burdens of $200+ billion in the US and about $1 trillion in lost global productivity, while multiple economic and trial findings report outcomes such as CBT for depression fitting common NICE cost per QALY thresholds and DBT reducing self harm frequency by about 40% over one year.
References
- 1ncbi.nlm.nih.gov/pmc/articles/PMC3085904/
- 5ncbi.nlm.nih.gov/pmc/articles/PMC3382284/
- 27ncbi.nlm.nih.gov/pmc/articles/PMC4485899/
- 68ncbi.nlm.nih.gov/pmc/articles/PMC3225225/
- 74ncbi.nlm.nih.gov/pmc/articles/PMC4165800/
- 75ncbi.nlm.nih.gov/pmc/articles/PMC5729971/
- 79ncbi.nlm.nih.gov/pmc/articles/PMC3101855/
- 2pubmed.ncbi.nlm.nih.gov/15255063/
- 4pubmed.ncbi.nlm.nih.gov/11507484/
- 7pubmed.ncbi.nlm.nih.gov/15596223/
- 10pubmed.ncbi.nlm.nih.gov/16945967/
- 11pubmed.ncbi.nlm.nih.gov/20614795/
- 12pubmed.ncbi.nlm.nih.gov/17400019/
- 13pubmed.ncbi.nlm.nih.gov/24107657/
- 14pubmed.ncbi.nlm.nih.gov/17418519/
- 15pubmed.ncbi.nlm.nih.gov/21248875/
- 16pubmed.ncbi.nlm.nih.gov/20062764/
- 17pubmed.ncbi.nlm.nih.gov/29789721/
- 19pubmed.ncbi.nlm.nih.gov/21813945/
- 20pubmed.ncbi.nlm.nih.gov/15901867/
- 21pubmed.ncbi.nlm.nih.gov/20194533/
- 22pubmed.ncbi.nlm.nih.gov/24879809/
- 24pubmed.ncbi.nlm.nih.gov/20332113/
- 25pubmed.ncbi.nlm.nih.gov/20831529/
- 26pubmed.ncbi.nlm.nih.gov/11052216/
- 28pubmed.ncbi.nlm.nih.gov/19109937/
- 29pubmed.ncbi.nlm.nih.gov/16411530/
- 30pubmed.ncbi.nlm.nih.gov/11456132/
- 31pubmed.ncbi.nlm.nih.gov/19131456/
- 47pubmed.ncbi.nlm.nih.gov/24321892/
- 48pubmed.ncbi.nlm.nih.gov/11999117/
- 49pubmed.ncbi.nlm.nih.gov/25472399/
- 50pubmed.ncbi.nlm.nih.gov/24001306/
- 51pubmed.ncbi.nlm.nih.gov/25211008/
- 52pubmed.ncbi.nlm.nih.gov/17196020/
- 53pubmed.ncbi.nlm.nih.gov/19026349/
- 54pubmed.ncbi.nlm.nih.gov/21340856/
- 55pubmed.ncbi.nlm.nih.gov/24227761/
- 69pubmed.ncbi.nlm.nih.gov/25900100/
- 72pubmed.ncbi.nlm.nih.gov/23598238/
- 73pubmed.ncbi.nlm.nih.gov/21098190/
- 76pubmed.ncbi.nlm.nih.gov/28063493/
- 77pubmed.ncbi.nlm.nih.gov/19779318/
- 78pubmed.ncbi.nlm.nih.gov/23892472/
- 80pubmed.ncbi.nlm.nih.gov/26209760/
- 81pubmed.ncbi.nlm.nih.gov/25543293/
- 82pubmed.ncbi.nlm.nih.gov/27418475/
- 83pubmed.ncbi.nlm.nih.gov/16678579/
- 3apa.org/pubs/journals/releases/amp-a0032512.pdf
- 59apa.org/workforce/forecast
- 6effectivehealthcare.ahrq.gov/products/psychotherapy-for-depression/research-protocol
- 8nice.org.uk/guidance/CG90/evidence
- 9nice.org.uk/guidance/cg90/evidence
- 23nice.org.uk/guidance/cg113/evidence
- 57nice.org.uk/guidance/ng222/evidence
- 70nice.org.uk/guidance/ta226/evidence
- 71nice.org.uk/process/pmg9/chapter/6-conditions-for-which-nice-makes-guidance
- 18thelancet.com/journals/lancet/article/PIIS0140-6736(08)61167-6/fulltext
- 32samhsa.gov/data/report/2021-nsduh-mental-health-state-estimates
- 39samhsa.gov/data/report/2021-national-survey-drug-use-and-health-nsduh
- 44samhsa.gov/data/report/2021-national-survey-drug-use-and-health-nsduh/mental-health
- 45samhsa.gov/data/report/2021-nsduh-state-prevalence-estimates
- 33cdc.gov/nchs/products/databriefs/db377.htm
- 34ghdx.healthdata.org/gbd-results-tool?params=gbd-api-params
- 35who.int/publications/i/item/9789240031593
- 36who.int/news-room/fact-sheets/detail/depression
- 37who.int/news-room/fact-sheets/detail/anxiety-disorders
- 38who.int/news-room/fact-sheets/detail/mental-disorders
- 40who.int/publications/i/item/9789241563949
- 43who.int/news-room/fact-sheets/detail/suicide
- 41oecd.org/health/health-at-a-glance-2019-health-inequalities.htm
- 42vizhub.healthdata.org/gbd-results/
- 46digital.nhs.uk/data-and-information/publications/statistical/adult-mental-health-in-england-results-from-the-2014-survey
- 61digital.nhs.uk/data-and-information/publications/statistical/psychological-therapies-annual-report
- 56nimh.nih.gov/health/topics/psychotherapies
- 65nimh.nih.gov/health/statistics/mental-illness
- 58aamc.org/media/54641/download
- 60stats.oecd.org/index.aspx?queryid=30169
- 62aihw.gov.au/reports/mental-health-services/mental-health-services
- 63aihw.gov.au/reports/mental-health-services/mental-health-services/contents/interactive-data
- 64nami.org/mhstats
- 66ahrq.gov/research/findings/final-reports/iim/reports/mental-illness.html
- 67rand.org/pubs/research_reports/RR1264.html